Imminent arrival of dolutegravir stocks in the Western Cape

Organisation: Position: Deadline Date: Location:

Western Cape Health is expecting to receive stock of a new antiretroviral (ARV) treatment called dolutegravir (DTG) by September, a drug that can be used in conjunction with other ARVs as a first and second-line treatment. A Cape Argus report says this is according to spokesperson, Mark van der Heever, who also said they would only begin implementation once sufficient stock is available.

DTG was recently approved by the World Health Organisation (WHO), after preliminary results of a 96-week trial, that was conducted by a Johannesburg-based research group from the University of the Witwatersrand.

The report says according to national training co-ordinator for the Treatment Action Campaign, Luckyboy Mkhondwane, the smaller dosages of DTG will make adherence easier and storage more manageable.

Cape Argus report (subscription needed)

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.